Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.750
-0.090 (-3.17%)
At close: Mar 12, 2026, 4:00 PM EDT
2.760
+0.010 (0.36%)
After-hours: Mar 12, 2026, 7:46 PM EDT

Gain Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-18.59-20.41-22.27-17.59-13.89-3.58
Depreciation & Amortization
0.090.080.080.060.020.01
Stock-Based Compensation
1.662.393.261.530.840.08
Other Adjustments
1.290.14-0.38-0.211-
Change in Receivables
----0.01-0
Changes in Accounts Payable
---1.07-0.520.4
Changes in Accrued Expenses
-0.650.27-0.690.710.670.17
Changes in Unearned Revenue
-1.19-0.851.09-0.210.03-0.13
Changes in Other Operating Activities
-1.06-0.50.05-0.05-0.52-0.19
Operating Cash Flow
-18.45-18.87-18.87-14.69-12.37-3.24
Capital Expenditures
-0-0.02-0.02-0.12-0.09-0.02
Purchases of Investments
---1.96-17.74--
Proceeds from Sale of Investments
-0.06512.193.08--
Investing Cash Flow
-0.044.9810.22-14.77-0.09-0.02
Long-Term Debt Issued
-----0.74
Long-Term Debt Repaid
-0.09-0.09-0.09-0.08-0.02-
Net Long-Term Debt Issued (Repaid)
-0.09-0.09-0.09-0.08-0.020.74
Issuance of Common Stock
8.0813.3812.73-42.640
Net Common Stock Issued (Repurchased)
8.0813.3812.73-42.640
Issuance of Preferred Stock
-----10.22
Net Preferred Stock Issued (Repurchased)
-----10.22
Other Financing Activities
--0.28---0.85-0.47
Financing Cash Flow
7.9913.0112.64-0.0841.7710.49
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.27-0.530.49-0.020.1-0.04
Net Cash Flow
-10.24-1.414.49-29.5729.417.19
Free Cash Flow
-18.45-18.9-18.88-14.81-12.46-3.26
FCF Margin
---34217.53%-10571.20%-7551.72%-11291.38%
Free Cash Flow Per Share
-0.65-0.83-1.45-1.25-1.23-1.22
Levered Free Cash Flow
-21.5-21.52-21.85-16.21-14.33-2.6
Unlevered Free Cash Flow
-20.79-21.92-21.82-16.41-14.25-3.25
Updated Aug 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q